Saturn Petcare made its Vigo County plans official last month. (photo courtesy of the IEDC)
TERRE HAUTE -
As Terre Haute officials close on the sale of a portion of a once high-profile property, they are also celebrating the latest in a string of economic developments wins. Germany-based Saturn Petcare Inc. will Wednesday close on its purchase of part of the former Pfizer Inc. (PFE) property as it moves forward with plans to establish its first U.S. operations in Vigo County. Last month, the pet food manufacturer made its plans official to invest more than $38 million to renovate a 350,000-square-foot facility in the Vigo County Industrial Park II and create up to 200 jobs.
Terre Haute Economic Development Corp. Executive Director Steve Witt says Saturn Petcare is one of four recent economic development deals, with “more in the queue.”
The facility will initially house production of wet pet food for cats and dogs with production slated to begin in June 2020.
The company had previously planned to locate in the former Kellogg's building in Seelyville, though plans changed after both companies failed to come to a purchase agreement.
“We’ve been talking with Saturn Petcare for three or four years now,” said Witt. “They’re going to be a great tenant and great member of our community and we’re very excited.”
Pfizer had been one of Terre Haute’s largest and most important employers since the 1940’s. In 2008, the company stunned west central Indiana when it announced it was halting production of the once-promising inhaled diabetes drug Exubera due to lower-than-expected sales.
The move eventually eliminated more than 700 high-paying jobs and with them one of the city’s iconic corporate names.
Hopes were raised in 2012, when California-based NantWorks said it would invest $120 million to locate a pharmaceutical manufacturing on the former Pfizer property, creating more than 230 jobs.
However, plans for Nantworks Terre Haute ultimately fizzled with the new owners blaming changing market demands.
Witt says Saturn Petcare is one of four recent economic development deals, with “more in the queue.”
By Kate Arndt Financial Planning Coordinator, Bedel Financial Consulting Inc.
The 2018 tax filing deadline came and went. Whew! But for some Americans, the tax headache has just begun. This year was the first filing under the Tax Cuts and Jobs Act and while some taxpayers saw larger refunds others received a rude awakening. If you’re reeling from a large tax burden, this article is for you. The Root of the Problem Remember how excited you were when you received your first paycheck—followed by dismay when you saw how much was taken out for taxes.
The city of Gary is facing challenges as it tries to rejuvenate retail business in the city. In an interview with our partners at The Times of Northwest Indiana, Aaron McDermott, president of Latitude Commercial Real Estate Services in Schererville, says the challenge is due to the perception, proximity and demographics associated with Gary.
The developers of a $34 million redevelopment project in downtown Fort Wayne have announced a new partnership. Cincinnati-based The Model Group says it is working with Cunningham Restaurant Group to bring a "new and unique" restaurant experience to The Landing.
Ball State University’s Miller College of Business has been recognized as one of The 30 Best Online MBA Degree Programs by MBA Central. The website details 30 programs across the nation and praises Ball State’s program for its variety and affordability.
Social impact investing is a fast-growing sector driven by investors who want to use private capital to further the public good. This industry provides a unique opportunity for results-oriented social entrepreneurs to invest in businesses, funds and nonprofits with the intention of generating positive, measurable social change alongside financial return. By engaging in impact investing, investors can align their investment portfolios with their philanthropic priorities.
Indianapolis-based Eli Lilly and Co. (NYSE: LLY) and Avidity Biosciences Inc. have announced a new partnership. The global licensing and research collaboration will work toward the discovery, development and commercialization of new medicines in immunology and other areas.